Dr. Aditya Bardia provides an overview of the current standard of care in the first-line setting, emphasizing the established role of endocrine therapy combined with CDK4/6 inhibitors.
Back
Advancing Precision Endocrine Therapy in ESR1-Mutant Metastatic Breast Cancer
This program focuses on integrating emerging oral selective estrogen receptor degraders (SERDs) into the treatment of ER-positive, HER2-negative metastatic breast cancer. Drs. Jason Mouabbi and Aditya Bardia review current and investigational agents such as elacestrant, imlunestrant, camizestrant, giredestrant, and others, emphasizing differences in tolerability and side-effect profiles. Oral SERDs are generally better tolerated than traditional endocrine therapies, with side effects ranging from gastrointestinal discomfort to bradycardia and visual disturbances, highlighting the importance of aligning therapy choice with patient lifestyle and preferences. Combination strategies with targeted therapies, including CDK4/6 inhibitors and everolimus, show enhanced efficacy but require careful consideration of overlapping toxicities. Using a case-based approach, the program demonstrates practical decision-making, including sequencing, monitoring with scans, tumor markers, and plasma-based genotyping, and underscores the role of patient-centered care. The overarching takeaway is the critical importance of molecular testing to identify ESR1 and other actionable mutations, enabling personalized, effective, and safe therapy selection.
Advancing Precision Endocrine Therapy in ESR1-Mutant Metastatic Breast Cancer
Episodes
All
All
In this segment, Dr. Jason Mouabbi and Dr. Bardia explore the growing importance of ESR1 mutations in the management of ER-positive, HER2-negative metastatic breast cancer, particularly after progression on CDK4/6 inhibitor–based therapy.
Why ESR1 mutations rise after CDK4/6 therapy, when to retest via liquid biopsy, and how low VAF still guides SERD choices.
Oral SERDs transform metastatic breast cancer care, with elacestrant boosting outcomes in ESR1-mutant disease and showing strong real-world progression-free survival.
Expert guidance on post-CDK4/6 metastatic breast cancer care, using liquid biopsy mutations to tailor oral SERDs versus targeted doublets for best outcomes.
Experts compare oral SERDs’ side effects, quality-of-life gains, and why brief ESR1 testing delays help choose smarter ER+ breast cancer therapy.
New data highlight oral SERD combination therapies boosting progression-free survival, while raising toxicity and reshaping when ESR1 mutation testing guides treatment choices.
Explore oral treatment choices after CDK4/6 progression in ER+ metastatic breast cancer, using ESR1/PIK3CA ctDNA plus scans and markers to track response.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5